NASDAQ:CYCC Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis → Are you prepared for a financial lockdown? (From Weiss Ratings) (Ad) Free CYCC Stock Alerts $1.61 -0.08 (-4.60%) (As of 11:02 AM ET) Add Compare Share Share Today's Range$1.60▼$1.6950-Day Range$1.36▼$2.8452-Week Range$1.30▼$13.20Volume10,058 shsAverage Volume545,923 shsMarket Capitalization$2.35 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cyclacel Pharmaceuticals alerts: Email Address Cyclacel Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside550.9% Upside$11.00 Price TargetShort InterestHealthy6.90% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.93) to ($4.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.57 out of 5 stars 3.3 Analyst's Opinion Consensus RatingCyclacel Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCyclacel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Cyclacel Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.90% of the float of Cyclacel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclacel Pharmaceuticals has recently decreased by 34.96%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCyclacel Pharmaceuticals does not currently pay a dividend.Dividend GrowthCyclacel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CYCC. Previous Next 2.2 News and Social Media Coverage News SentimentCyclacel Pharmaceuticals has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cyclacel Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for CYCC on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.00% of the stock of Cyclacel Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.Read more about Cyclacel Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cyclacel Pharmaceuticals are expected to grow in the coming year, from ($4.93) to ($4.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclacel Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclacel Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyclacel Pharmaceuticals has a P/B Ratio of 2.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cyclacel Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsAre you prepared for a financial lockdown?A new kind of American dystopia is being built before our eyes, and most people have no idea what's happening. That's why I've recorded this urgent message to give you all the details on how to prepare … Including three steps to take right now.Click here to watch my video before it's too late. About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC)Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Read More CYCC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYCC Stock News HeadlinesJune 12, 2024 | americanbankingnews.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded to "Hold" at StockNews.comJune 4, 2024 | globenewswire.comCyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingMay 14, 2024 | investorplace.comCYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q1 2024May 8, 2024 | globenewswire.comCyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesApril 30, 2024 | msn.comWhy Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?April 30, 2024 | investorplace.comWhy Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?April 30, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesApril 29, 2024 | marketwatch.comCyclacel Pharmaceuticals Shares Up 72% After Hours on Withdrawal of OfferingApril 26, 2024 | marketwatch.comCyclacel Pharmaceuticals Shares Hit All-Time Low on Planned Equity SaleApril 25, 2024 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near FutureApril 1, 2024 | globenewswire.comCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for CancerMarch 27, 2024 | money.usnews.comCyclacel Pharmaceuticals IncMarch 21, 2024 | seekingalpha.comCyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | msn.comCYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023March 19, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 13, 2024 | globenewswire.comCyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024March 6, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditFebruary 22, 2024 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (CYCCP)February 20, 2024 | globenewswire.comCyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceFebruary 15, 2024 | finance.yahoo.comCyclacel Pharmaceuticals Inc. (UXI.SG)January 8, 2024 | finance.yahoo.comCyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price RequirementDecember 22, 2023 | msn.comWhy Cyclacel Pharmaceuticals (CYCC) Shares Are Getting ObliteratedSee More Headlines Receive CYCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/17/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYCC CUSIPN/A CIK1130166 Webwww.cyclacel.com Phone(908) 517-7330Fax866-271-3466Employees2,018Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+550.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($22.4430) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,560,000.00 Net Margins-4,401.34% Pretax Margin-5,061.69% Return on Equity-1,009.04% Return on Assets-180.03% Debt Debt-to-Equity RatioN/A Current Ratio0.58 Quick Ratio0.58 Sales & Book Value Annual Sales$420,000.00 Price / Sales5.87 Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book2.96Miscellaneous Outstanding Shares1,460,000Free Float1,346,000Market Cap$2.47 million OptionableOptionable Beta0.58 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Spiro George Rombotis (Age 65)President, CEO & Executive Director Comp: $612.47kMr. Paul McBarron (Age 63)Executive VP of Finance, CFO, COO, Secretary & Executive Director Comp: $321.61kDr. Brian Schwartz M.D. (Age 62)Interim Chief Medical Officer & Director Comp: $53kMs. Gill Christie (Age 67)Director of Human Resources Grace KimInvestor Relations ExecutiveKey CompetitorsKintara TherapeuticsNASDAQ:KTRAEterna TherapeuticsNASDAQ:ERNAFSD PharmaNASDAQ:HUGEMoleculin BiotechNASDAQ:MBRXCan-Fite BioPharmaNYSE:CANFView All CompetitorsInsiders & InstitutionsAcadian Asset Management LLCSold 9,938 shares on 5/10/2024Ownership: 1.084%Spiro George RombotisBought 6,070 shares on 12/21/2023Total: $20,091.70 ($3.31/share)Paul McbarronBought 1,886 shares on 12/21/2023Total: $6,242.66 ($3.31/share)View All Insider TransactionsView All Institutional Transactions CYCC Stock Analysis - Frequently Asked Questions Should I buy or sell Cyclacel Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CYCC shares. View CYCC analyst ratings or view top-rated stocks. What is Cyclacel Pharmaceuticals' stock price target for 2024? 2 brokerages have issued 12 month price targets for Cyclacel Pharmaceuticals' stock. Their CYCC share price targets range from $11.00 to $11.00. On average, they anticipate the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 550.9% from the stock's current price. View analysts price targets for CYCC or view top-rated stocks among Wall Street analysts. How have CYCC shares performed in 2024? Cyclacel Pharmaceuticals' stock was trading at $2.67 at the beginning of 2024. Since then, CYCC stock has decreased by 36.7% and is now trading at $1.69. View the best growth stocks for 2024 here. Are investors shorting Cyclacel Pharmaceuticals? Cyclacel Pharmaceuticals saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 94,500 shares, a decrease of 35.0% from the May 15th total of 145,300 shares. Based on an average daily trading volume, of 831,600 shares, the short-interest ratio is presently 0.1 days. Approximately 6.9% of the company's stock are sold short. View Cyclacel Pharmaceuticals' Short Interest. When is Cyclacel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our CYCC earnings forecast. How were Cyclacel Pharmaceuticals' earnings last quarter? Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) released its quarterly earnings results on Tuesday, May, 14th. The biotechnology company reported ($2.27) EPS for the quarter, beating the consensus estimate of ($4.93) by $2.66. The biotechnology company had revenue of $0.03 million for the quarter. Cyclacel Pharmaceuticals had a negative trailing twelve-month return on equity of 1,009.04% and a negative net margin of 4,401.34%. During the same quarter in the prior year, the company earned ($7.05) EPS. When did Cyclacel Pharmaceuticals' stock split? Shares of Cyclacel Pharmaceuticals reverse split on the morning of Monday, December 18th 2023. The 1-15 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO? 1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Cyclacel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA). Who are Cyclacel Pharmaceuticals' major shareholders? Cyclacel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (1.08%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Paul Mcbarron, Sam L Barker and Spiro George Rombotis. View institutional ownership trends. How do I buy shares of Cyclacel Pharmaceuticals? Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYCC) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | Sponsored(Free Workshop) Advanced “bug-out bag” hacks!“Do you have a ‘bug-out bag’ (survival kit) ready to grab-and-go when a disaster or other crisis strikes?” ...Warrior Life | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.